ROSA MARIA AYALA DIAZ

Has grant

Full Professor

Universidad Complutense de Madrid

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Cancer Biology Cancer Biology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Rosa Maria Ayala Diaz is a Full Professor at Universidad Complutense de Madrid, Spain. Her research primarily focuses on hematology, particularly in acute myeloid leukemia, myelofibrosis, and the role of genetic mutations in treatment outcomes. Recent publications include work on the impact of somatic mutations on thrombosis risk in myelofibrosis and the evaluation of next-generation sequencing for diagnosing mutations in acute myeloid leukemia.

Recent Grants

Grant: Close

MEDICINA DE PRECISIÓN EN LEUCEMIA MIELOIDE AGUDA: DETECCIÓN DE PACIENTES RESISTENTES A DROGAS Y DESARROLLO DE NUEVAS APROXIMACIONES TERAPÉUTICAS.

Open Date: 2020-01-01

Close Date: 2022-12-01

Grant: Close

Alteraciones moleculares involucradas en los mecanismos de refractariedad y recaída de la Leucemia Mieloide Aguda: Implicaciones terapéuticas.

Open Date: 2017-01-01

Close Date: 2019-12-31

Grant: Close

Implicaciones clínicas de la detección de mutaciones recurrentes por secuenciación masiva de paneles en Leucemia Mieloide Aguda, y correlación con la sensibilidad a fármacos antileucemia

Open Date: 2014-01-01

Close Date: 2016-12-31

Articles (26)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (27)

Cristina Jiménez

SPAIN

ROSA MARIA AYALA DIAZ

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (26)

The JAK2 46/1 haplotype influences PD-L1 expression

Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA Study

Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma

Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy.

Prognostic relevance of variant allelic frequency for treatment outcomes in patients with acute myeloid leukemia: a study by the Spanish PETHEMA registry.

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience

Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Validation of mutated <i>CEBPA</i> bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry.

Should we move to a genomic classification of neutrophilic myeloid neoplasms?

Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (<i>PSMC</i>) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia

Short-chain fatty acid production by gut microbiota predicts treatment response in multiple myeloma

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

Impact of IPSS-M implementation in real-life clinical practice

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis

NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network

Collaborators (27)

Cristina Jiménez

Jesús María Hernández-Rivas

Michal Simicek

Iria Vázquez Urio

Nicholas Cross

Juan Carlos Hernandez-Boluda

Rebeca Rodríguez-Veiga

Miguel Angel Piris

PAULA DE TOLEDO

Frederik Damm

Joaquín Martínez‐López

Juan Manuel Alonso-Dominguez

Francisca Ferrer‐Marín

K. Martin Kortüm

Maria Linares

David Perez-Rey

Alejandro Martín Muñoz

MJ Calasanz

Ramón García-Sanz

Joaquin Martinez-Lopez

Carolina Martínez-Laperche

Tim Somervaille

María Tiana Cerrolaza

Lars Bullinger

Norma C. Gutiérrez

Armando Reyes-Palomares

Valentin Garcia

Make your next move.